PAHC CEO reports sales on 10/22–10/24/2025 under 10b5‑1 plan

Phibro Animal Health (PAHC) insider filings show sales of Class A common stock tied to a pre‑set Rule 10b5‑1 plan by BFI Co., LLC, over which CEO and director Jack Bendheim exercises voting and dispositive power.

Rhea-AI Filing Summary

Phibro Animal Health (PAHC) insider filings show sales of Class A common stock tied to a pre‑set Rule 10b5‑1 plan by BFI Co., LLC, over which CEO and director Jack Bendheim exercises voting and dispositive power. Reported transactions occurred on 10/22/2025 (11,859 shares at a weighted average price of $40.2692), 10/23/2025 (3,520 shares at $40.1796), and 10/24/2025 (3,520 shares at $41.749).

Following these trades, 55,000 shares were beneficially owned indirectly via BFI, and 16,840 shares were held directly. The 10b5‑1 trading plan was adopted on May 30, 2025.

Insider Trade Summary

Net Seller: 18,899 shares

Net Sell 4 txns

Insider BENDHEIM JACK, BFI Co., LLC

Role President and CEO | 10% Owner

Sold 18,899 shs ($766K)

Type	Security	Shares	Price	Value
Sale	Class A Common Stock	3,520	$41.749	$147K
Sale	Class A Common Stock	3,520	$40.1796	$141K
Sale	Class A Common Stock	11,859	$40.2692	$478K
holding	Class A Common Stock	--	--	--

Holdings After Transaction: Class A Common Stock — 55,000 shares (Indirect, See); Class A Common Stock — 16,840 shares (Direct)

Footnotes (6)

1. F1. The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.
2. F2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $41.555. The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. F3. The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
4. F4. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.46.
5. F5. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.265 to $42.28.
6. F6. The reported securities are directly held by Jack Bendheim.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did PAHC report?

Sales of Class A common stock on 10/22/2025 (11,859 shares), 10/23/2025 (3,520), and 10/24/2025 (3,520) under a Rule 10b5‑1 plan.

What prices were reported for the PAHC insider sales?

Weighted average prices were $40.2692 on 10/22/2025, $40.1796 on 10/23/2025, and $41.749 on 10/24/2025.

Who executed the sales and what is the relationship to PAHC?

The shares were sold by BFI Co., LLC; Jack Bendheim, PAHC’s President and CEO, director, and 10% owner, exercises voting and dispositive power over BFI.

How many PAHC shares are beneficially owned after the transactions?

55,000 shares were owned indirectly via BFI after the reported trades, and 16,840 shares were held directly.

Was there a Rule 10b5‑1 trading plan in place?

Yes. The reported sales were effected pursuant to a Rule 10b5‑1 trading plan adopted on May 30, 2025 by BFI Co., LLC.

What price ranges did the PAHC sales occur within?

10/22: $40.00–$41.555; 10/23: $40.00–$40.46; 10/24: $41.265–$42.28, per weighted‑average footnotes.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/24/2025 - 07:06 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BENDHEIM JACK

(Last) (First) (Middle)

300 FRANK W. BURR BLVD., STE 21

(Street)

TEANECK NJ 07666

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PHIBRO ANIMAL HEALTH CORP [ PAHC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
10/22/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	10/22/2025		S(1)		11,859	D	$40.2692(2)	62,040	I	See(3)
Class A Common Stock	10/23/2025		S(1)		3,520	D	$40.1796(4)	58,520	I	See(3)
Class A Common Stock	10/24/2025		S(1)		3,520	D	$41.749(5)	55,000	I	See(3)
Class A Common Stock								16,840	D(6)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

1. Name and Address of Reporting Person^*

BENDHEIM JACK

(Last) (First) (Middle)

300 FRANK W. BURR BLVD., STE 21

(Street)

TEANECK NJ 07666

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

1. Name and Address of Reporting Person^*

BFI Co., LLC

(Last) (First) (Middle)

300 FRANK W. BURR BLVD., STE 21

(Street)

TEANECK NJ 07666

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

Explanation of Responses:

1. The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $41.555. The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

4. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.46.

5. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.265 to $42.28.

6. The reported securities are directly held by Jack Bendheim.

	/s/ Judith Weinstein, as Attorney-in-Fact for Jack Bendheim	10/24/2025
	/s/ Judith Weinstein, as Attorney-in-Fact for BFI Co., LLC	10/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.